Compare Nu Holdings Ltd (NU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Smith & Nephew plc — how do they compare? Nu Holdings Ltd trades at $15.94 (market cap $74.30B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Nu Holdings Ltd is far larger — about 6.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Smith & Nephew plc for 121 Days on average.
| NU | SNN | |
|---|---|---|
Market Cap | $74.30B | $11.10B |
Volume | 80,294,805 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $18.76 | $37.17 |
52-Week Low | $11.60 | $26.42 |
Typical Hold Time | 53 Days | 121 Days |
Enterprise Value | $96.91B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.92, up 2.18% with bullish technical signals from moving averages. The company demonstrates strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights acquisition speculation around Monzo and Goldman Sachs' bullish stance, though the stock remains volatile amid mixed earnings performance with two misses and one beat in recent quarters.
The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target, though risks include credit concentration (85% customer concentration in Brazil) and rising delinquencies. The stock trades near resistance at $16 with RSI at 91 suggesting overbought conditions, requiring careful entry timing despite strong growth fundamentals.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
